Finland· FI-REL-REL26154
Cervarix
A humaner papillomvirus (typen 16, 18) product containing human papillomavirus type 16, l1 surface protein + human papillomavirus type 18, l1 surface protein, registered in Finland by GlaxoSmithKline Biologicals SA. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Humaner papillomvirus (typen 16, 18) is registered in 10 of 19 countries.
Countries holding a registration under ATC J07BM02 (humaner papillomvirus (typen 16, 18)), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Humaner papillomvirus (typen 16, 18) · ATC J07BM02
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
Fimea (Finland)- Active substance
- Human papillomavirus Type 16, L1 surface protein + Human papillomavirus Type 18, L1 surface protein
- Manufacturer
- GlaxoSmithKline Biologicals SA
- Country
- Finland (FI)
- ATC code
- J07BM02
- ATC class
- Humaner Papillomvirus (Typen 16, 18)
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BM02
Humaner papillomvirus (typen 16, 18), as other registers publish it.
- BelgiumCervarixGlaxoSmithKline Biologicals
- IcelandCervarixGlaxoSmithKline Biologicals S.A.*
- BelgiumCervarixGlaxoSmithKline Biologicals
- PolandCervarixGlaxoSmithKline Biologicals S.A.
- IcelandCervarixGlaxoSmithKline Biologicals S.A.*
- PolandCervarixGlaxoSmithKline Biologicals S.A.
- IcelandCervarixGlaxoSmithKline Biologicals S.A.*
- DenmarkCervarixGlaxoSmithKline Biologicals S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9b4981a9-ab3f-4fbd-af28-911511328f91 GET /v1/drugs/9b4981a9-ab3f-4fbd-af28-911511328f91?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, suspensio",
"route": "Lihakseen",
"ddd_unit": null,
"strength": null,
"atc_label": "ihmisen papilloomavirus (tyyppi 16, 18) -rokote",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/07/419/001-003,010-012",
"fimea_rel_id": "REL26154",
"authorised_at": "2007-09-20"
}See everything about humaner papillomvirus (typen 16, 18).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.